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Abstract
Background—Fibrinogen is both central to blood coagulation and an acute phase reactant. We
aimed to identify common variants influencing circulation fibrinogen levels.
Methods and Results—We conducted a genome-wide association analysis on six population-
based studies, the Rotterdam Study, the Framingham Heart Study, the Cardiovascular Health Study,
the Atherosclerosis Risk in Communities Study, the MONICA/KORA Augsburg Study, and the
British 1958 Birth Cohort Study, including 22,096 participants of European ancestry. Four loci were
marked by one or more single nucleotide polymorphisms (SNPs) that demonstrated genome-wide
significance (p<5.0×10−8). These included a SNP located in the fibrinogen β chain (FGB) gene and
three SNPs representing newly identified loci. The high-signal SNPs were rs1800789 in exon 7 of
FGB (p=1.8×10−30), rs2522056 downstream from the interferon regulatory factor 1 (IRF1) gene (p=
1.3×10−15), rs511154 within intron 1 of the propionyl coenzyme A carboxylase (PCCB) gene (p=
5.9×10−10), and rs1539019 on the NLR family, pyrin domain containing 3 isoforms (NLRP3) gene
(p = 1.04×10−8).
Conclusions—Our findings highlight biological pathways that may be important in regulation of
inflammation underlying cardiovascular disease.
Keywords
genome-wide association; fibrinogen; gene; FGB; IRF1; PCCB; NLRP3
Elevated levels of fibrinogen within or above the normal range are consistently associated with
an increased risk of cardiovascular disease.1 Fibrinogen has a key role in blood coagulation
but is also known as a marker of inflammation. Studies in persons of European ancestry have
estimated the heritability of multivariable-adjusted fibrinogen levels from 24% in multiplex
families2 to more than 50% in twins.3 The three genes encoding the three fibrinogen protein
chains explain only a small part of the total estimated genetic variance of circulating levels of
fibrinogen.4
The objective of this study was to identify novel genetic loci related to plasma fibrinogen levels.
A meta-analysis of genome-wide association (GWA) findings was conducted on six
population-based studies. We analyzed GWA data of 2,661,766 SNPs from one or more studies
from a total of 22,096 participants of European descent.
Methods
The setting for this meta-analysis is primarily the Cohorts for Heart and Aging Research in
Genomic Epidemiology (CHARGE) Consortium.5 CHARGE includes the Rotterdam Study
(RS), the Framingham Heart Study (FHS), the Cardiovascular Health Study (CHS), and the
Dehghan et al. Page 2
Circ Cardiovasc Genet. Author manuscript; available in PMC 2010 April 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Atherosclerosis Risk in Communities (ARIC) Study. In addition, data from the British 1958
Birth Cohort (B58C) and the MONICA/KORA Augsburg Study (KORA) has been included.
Rotterdam Study (RS)
The RS is a prospective, population-based cohort study of determinants of several chronic
diseases in older adults.6 In brief, the study comprised 7,983 inhabitants of Ommoord, a district
of Rotterdam in the Netherlands, who were 55 years or over. The baseline examination took
place between 1990-1993.
Genotyping was conducted using the Illumina 550K array. SNPs were excluded for minor
allele frequency ≤1%, Hardy-Weinberg equilibrium (HWE) p<10−5, or SNP call rate ≤90%
resulting in data on 530,683 SNPs. Imputation was done with reference to HapMap release 22
CEU using the maximum likelihood method implemented in MACH. The final population for
this fibrinogen analysis comprised 2,068 individuals.
Framingham Heart Study (FHS)
The FHS started in 1948 with 5,209 randomly ascertained participants from Framingham,
Massachusetts, US, who had undergone biannual examinations to investigate cardiovascular
disease and its risk factors.7 In 1971, the Offspring cohort8,9 (comprised of 5,124 children of
the original cohort, and the children's spouses) and in 2002, the Third Generation (consisting
of 4,095 children of the Offspring cohort), were recruited10. FHS participants in this study are
of European ancestry.
Genotyping was carried-out as a part of the SHARe project using the Affymetrix 500K mapping
array (250K Nsp and 250K Sty arrays) and the Affymetrix 50K supplemental gene focused
array on 9,274 individuals. Genotyping resulted in 503,551 SNPs with successful call rate
>95% and HWE p>10−6 on 8481 individuals with call rate >97%. Imputation of ~2.5 million
autosomal SNPs in HapMap with reference to release 22 CEU sample was conducted using
the algorithm implemented in MACH. The final population for fibrinogen analysis included
7,022 individuals (Original Cohort n=383, Offspring n=2,806, Third Generation n=3,833).
Cardiovascular Health Study (CHS)
The CHS is a population-based, observational study of risk factors for clinical and subclinical
cardiovascular diseases.11 The study recruited participants 65 years of age and older from four
US communities in two phases: 5,201 participants in 1989-1990, and 687 (primarily African
American participants) in 1992-1993. A GWA study was conducted in a subset of CHS
participants (n=3,980), all of whom were without clinical cardiovascular disease at their
baseline clinical visit and provided consent to use their DNA for research. The study sample
used in the fibrinogen analysis represented the first two of three rounds of genotyping, which
was a stratified probability sample. Weights were assigned to each observation to reflect the
likelihood of sampling from the 3,980 participants. The analysis was restricted to participants
of European decent.
Genotyping was performed using the Illumina 370 CNV BeadChip system. Samples were
excluded for sex mismatch, discordance with prior genotyping, or call rate <95%. SNPs were
excluded from analysis when monomorphic, when HWE p<10−5, and when call rates were
<95%. Imputation was performed using BIMBAM v0.95 with reference to HapMap CEU using
release 21A build. The population available for the fibrinogen analysis included 1,993
individuals.
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The Atherosclerosis Risk in Communities (ARIC)
The ARIC study is a longitudinal cohort study of atherosclerosis and its clinical sequelae. It
recruited a population-based sample of 15,792 men and women aged 45-64 years from four
US communities in 1987-89.12 The analysis was restricted to subjects of European decent.
Genotyping was performed using the Affymetrix Genome-Wide Human SNP Array 6.0. SNPs
were excluded for not being autosomal SNPs, not passing laboratory QC, no chromosome
location, minor allele frequency ≤1%, SNP call rate <90%, or HWE p<10−6. This resulted in
data on 716,442 SNPs. Imputation to HapMap SNPs was performed using MACH. After
excluding subjects who disallowed DNA use, subjects with a mismatch between called and
phenotypic sex, with a mismatch on >10 of 47 previously analyzed SNPs in ARIC, all but one
in sets of first degree relatives, and other individuals who were genetic outliers, the final
population for fibrinogen analysis comprised 8,051 individuals.
The MONICA/KORA Augsburg Study (KORA)
The presented data were derived from the third population-based Monitoring of Trends and
Determinants in Cardiovascular Disease (MONICA)/Cooperative Health Research in the
Region of Augsburg (KORA) survey S3.13 This cross-sectional survey covering the city of
Augsburg (Germany) and two adjacent counties was conducted in 1994/95 to estimate the
prevalence and distribution of cardiovascular risk factors among individuals aged 25 to 74
years as part of the WHO MONICA study. The MONICA/KORA S3 study comprises 4,856
subjects. Among them, 3,006 subjects participated in a follow-up examination of S3 in 2004/05
(MONICA/KORA F3). All participants underwent standardized examinations including blood
withdrawals for plasma and DNA. For the KORA genome-wide association study, 1,644
subjects, aged 45 to 69 years were selected from the KORA S3/F3 samples.
Genotyping was performed using the Affymetrix 500K Array Set. Samples were excluded for
sex mismatch, discordance with prior genotyping, or call rate <95%. SNPs were excluded from
analysis when monomorphic (MAF<0.01), when call rates per SNP were <0.1 and per
individual were <0.1. Imputation was done using maximum likelihood method implemented
in MACH 1.0. The final population available for the fibrinogen analysis included 1,523
individuals.
British 1958 birth cohort (B58C)
The B58C is a national population sample followed periodically from birth. At age 44-45 years,
9,377 cohort members were examined by a research nurse in the home as described previously.
14 For this study we used a total of 1,480 cell-line-derived DNA samples from unrelated
subjects of European ancestry, with nationwide geographic coverage, which were used as
controls by the Wellcome Trust Case Control Consortium (WTCCC).15
Genotyping was performed using the Affymetrix 500K Mapping Array Set using the call
algorithm CHIAMO as implemented by the WTCCC.15 Genotypes at other loci were imputed
by the program IMPUTE version 0.1.2, using 490,032 autosomal SNPs with CHIAMO calls
and the linkage disequilibrium patterns in the HapMap CEU panel. Analysis of imputed
genotypes used Marchini's SNPTEST version 1.1.3 and supplementary regression modeling
used STATA version 10.0. A final sample size of 1,459 individuals was included in the
fibrinogen analysis.
Measurement of fibrinogen
In the KORA study, fibrinogen was determined by an immunonephelometric method (Dade
Behring Marburg GmbH, Marburg, Germany) on a Behring Nephelometer II analyzer. FHS
study used the Clauss method16 in the offspring and the third generation subjects, and a
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modified method of Ratnoff and Menzie17 in the original cohort subjects. In the RS, fibrinogen
levels were derived from the clotting curve of the prothrombin time assay using Thromborel
S as a reagent on an automated coagulation laboratory 300 (ACL 300, Instrumentation
Laboratory, Zaventem, Belgium). The other studies used the Clauss method for measuring
plasma fibrinogen.16
Statistical analysis
Each study independently analyzed their genotype-phenotype data. Except for FHS, which has
a family structure, all studies conducted analyses of all directly genotyped and imputed SNPs
using linear regression on untransformed fibrinogen measures using an additive genetic model
adjusted for age, sex, and site of recruitment (if necessary). In FHS, a linear mixed effects
model was employed with a fixed additive effect for the SNP genotype, fixed covariate effects,
random family specific additive residual polygenic effects to account for within family
correlations18, and a random environment effect. In addition, FHS adjusted for population
stratification using principal components of the directly measured SNPs which were computed
using the Eigenstrat software.
To account for residual stratification, p-values were adjusted for genomic inflation. The
inflation of the association test statistic, stated as inflation factor lambda (λgc), was small for
all studies: 0.995 for RS, 1.016 for FHS, 1.031 for CHS, 1.024 for ARIC, 1.012 for KORA,
and 1.008 for B58C. Using the study-specific results, we conducted a fixed effect model meta-
analysis based on inverse-variance weighting. MetABEL, a package running under R was used
to perform the meta-analysis. We used Bonferroni correction to deal with the problem of
multiple testing. Simulation studies show that the effective number of independent tests in a
GWA analysis is nearly one million.19 Based on one million tests, we selected a p-value
threshold of 5×10−8 as the level of genome-wide significance.
In addition, we estimated the effect of the top SNPs in strata of sex and smoking status. Gene-
by-sex and gene-by-smoking interaction was tested in each study by introducing an interaction
term into the linear model. We used a sample size weighted meta-analysis to combine the
reported interaction p-values across studies for each of the top SNPs.
Replication in Women's Health Genome Study (WHGS)
We used the WHGS to replicate our genome wide significant findings and other loci for which
our meta-analysis generated more modest evidence of an association (p-value of 5×10−7).
Participants in WGHS are derived from the genetic arm of the Women's Health Study and
include American women with no prior history of cardiovascular disease, cancer, or other major
chronic illness who provided a baseline blood sample during the enrollment phase of the
Women's Health Study between 1992 and 1995.20 Fibrinogen levels were measured using an
immunoturbidimetric assay (Kamiya Biomedical, Seattle, Wash), which was standardized to
a calibrator from the World Health Organization. Genotyping was done using the Illumina
Infinium II assay to query a genome-wide set of 315,176 haplotype-tagging SNP markers
(Human HAP300 panel) as well as a focused panel of 45,882 missense and haplotype tagging
SNPs. For this analysis, the evaluation was performed on 17,686 non-diabetic individuals who
were of Caucasian ancestry and were not taking lipid-lowering agents. The GWA results of
the WHGS are reported in a companion manuscript.
Results
The sample size and participant characteristics from each study are shown in Table 1. A
quantile-quantile plot (Q-Q plot) of the observed against expected p-value distribution is shown
in Figure 1. Figure 2 illustrates the primary findings from the meta-analysis and presents p-
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values for each of the interrogated SNPs across the 22 autosomal chromosomes. A total of 73
SNPs (supplemental Table 1) exceeded the threshold of genome-wide significance and
clustered around four loci on chromosomes 1 (2 SNPs), 3 (12 SNPs), 4 (23 SNPs), and 5 (36
SNPs) (Figure 3).
The strongest statistical evidence for an association was for rs1800789 which is located at
4q31.3 in exon 7 of the fibrinogen ß (FGB) gene (minor allele frequency [MAF]: 0.20-0.24,
meta-analysis p-value = 1.75×10−30, fibrinogen level change per minor allele [Δ]: 0.087 g/L).
The other significant loci were marked by rs2522056, which is located at 5q23.3, 25 kb
downstream of the interferon regulatory factor 1 (IRF1) gene (MAF: 0.17-0.21, p =
1.3×10−15, Δ: −0.063 g/L), rs511154, which is located at 3q22.3, in intron 1 of the propionyl
coenzyme A carboxylase, beta polypeptide (PCCB) gene (MAF: 0.21-0.24, p = 5.94×10−10,
Δ: 0.045 g/L) and rs1539019 which is located at 1q44, on the NLR family, pyrin domain
containing 3 isoforms (NLRP3) gene (MAF: 0.37-0.42, p = 1.04×10−8, Δ: −0.038 g/L). Cohort-
specific findings are presented for the top SNP within each locus in Table 2. Results did not
change materially when we adjusted the model for other covariates (smoking, alcohol
consumption, body mass index, systolic blood pressure, triglyceride, total- and HDL-
cholesterol, diabetes, and cardiovascular disease) (data not shown). Table 3 shows the mean
and standard deviations for fibrinogen levels by genotype for each of the four SNPs.
We estimated the association of the four SNPs by sex and smoking status separately but none
of the SNPs showed a significantly different association between subgroups (Supplementary
Table 2 and 3).
A combined risk alleles score summarizing the number of risk alleles was associated with a
15% increase in overall mean fibrinogen level comparing subjects with no risk allele (mean
fibrinogen level 2.81 g/L) to subjects with six or more risk alleles (mean fibrinogen level 3.24
g/L). The genetic variants identified in our study explained less than 2% of the overall variance
in plasma fibrinogen in all studies except one.
To investigate the validity of our findings, we sought replication of the four loci using WHGS
data. Since WHGS did not genotype the identical SNPs as our six cohorts, the best proxy SNP
was used for replication. For rs1800789, rs2522056, rs511154, and rs1539019, we used WHGS
SNPs rs6056 (r2=0.95; p=8.04×10−39), rs1016988 (r2=0.80; p=1.24×10−12), rs684773 (r2=1.0;
p=1.92×10−5), and rs1539019 (p=2.89×10−4), respectively, as the proxy SNP. The direction
of each association in WHGS was consistent with our findings.
In addition to our four genome-wide significant loci, two other loci demonstrated multiple-
SNP hits with p-values <5×10−7: one on chromosome 2 (rs4251961, p=3.5×10−7) and one on
chromosome 14 (rs8017049, p= 5.6×10−7). When we examined the results for these two loci
in the WHGS data, we found evidence for replication on chromosome 2 (rs4251961 in WHGS,
p=8.5×10−3).
Discussion
We identified four loci associated with circulating fibrinogen level through a meta-analysis of
GWA data from six cohort studies comprising 22,096 subjects. We provide strong information
of the previously reported associations with the FGB locus. Three of our findings are newly
identified associations.
The most significant SNP in our study was rs1800789 which is located on the FGB gene. The
FGB gene encodes the fibrinogen ß chain. A well-characterized SNP at this locus is rs1800787
(−148C/T) which resides 965 base pairs away from our top SNP (rs1800789) and is in high
LD with it (D′~1.0, r2=0.91). It is known that rs1800787 directly affects gene transcription in
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basal and IL6-stimulated conditions in luciferase expression studies.21 Another well-
characterized SNP in this region is rs1800790 (455G/A), which is also in strong LD with
rs1800787, is known to be related to plasma fibrinogen 22 and showed a strong association
with fibrinogen levels in our study as well (p=5.04×10−27, Supplementary Table 1).
The second locus is located 25 kb downstream from the IRF1 gene on chromosome 5. IRF1 is
a member of the interferon regulatory transcription factor family and activates transcription of
interferon α and ß. IRF1 also functions as a transcription activator of genes induced by
interferon α, β and γ. Direct effects of interferons on fibrinogen have not previously been
described, but it is known that they play a role in the regulation of acute phase proteins. Notably,
the SNP is only 31 kb from a SNP strongly associated with Crohn's disease in a recent meta-
analysis (rs2188962, p<2.32×10−18).23 Individuals with inflammatory bowel disease (IBD),
including Crohn's disease, are at a threefold higher risk of venous thrombosis 24, accounting
for substantial morbidity and mortality in this group.25 Furthermore, multiple studies have
indicated significantly elevated levels of fibrinogen in IBD patients.26 This suggests that
IRF1 or nearby genes may contribute to Crohn's disease via a mechanism mediated through
an increase in acute phase responsiveness and fibrinogen levels.
The third locus on chromosome 3 is located in intron 1 of the PCCB gene. The PCCB gene is
responsible for a particular step in the breakdown of the amino acids isoleucine, methionine,
threonine, and valine. However, the available information about PCCB does not provide a
strong hypothesis about the putative function of the gene in regulation of fibrinogen levels.
The fourth locus on chromosome 1 is located on the NLRP3 gene. The NLRP3 gene encodes
a pyrin-like protein, which interacts with the apoptosis-associated speck-like protein
PYCARD/ASC and is a member of the NALP3 inflammasome complex.27 Activated NALP3
inflammasome drives processing of the pro-inflammatory cytokine pro-IL1ß to IL1ß. Recent
data indicate that the NALP3 inflammasome can be activated by endogenous ‘danger signals’
as well as compounds associated with pathogens and triggers an innate immune response. 28
The finding on chromosome 2 is located in the promoter region (1 kb upstream from the
transcription start site) of the interleukin-1 receptor antagonist (IL1RN) gene. Fibrinogen is an
acute phase protein that is regulated by cytokines, mainly IL1 and IL6, while the IL6-mediated
transcription of the fibrinogen gene is inhibited by IL1ß.29 This region has formerly reported
to be associated with fibrinogen levels; rs2232354, which is in high LD with our top SNP,
rs4251961, was associated with fibrinogen levels in an asymptomatic population.30
Our findings were replicated in WGHS. Two of our four SNPs are reported by WGHS as
genome-wide significant findings (rs6056 and rs1016988) and the other two have p-values
which suggest non-chance findings in a replication (rs684773 and rs1539019). These results
provide further credibility that our newly identified loci are valid.
We examined evidence for the top four fibrinogen loci among gene expression QTLs from
recent GWA studies in human liver tissues31 and lymphoblastoid cell lines.32 In liver tissues,
SNPs at the FGB locus were strongly associated with the expression of FGB (e.g., rs4508864,
p<1.20×10−8) as well as with other trans-located mRNAs. Likewise, we observed that several
SNPs in the region of the IRF1 locus were strongly associated with the expression of nearby
genes (including IRF1, LOC441108, and SLC22A5) in both liver tissues and lymphoblastoid
cell lines (e.g., rs2070729, p=4.9×10−10 for expression of the IRF1 gene). These results from
independent genome-wide association studies strongly suggest a functional basis for the
observed associations in the FGB and IRF1 loci.
Although heritability estimates for circulating fibrinogen are substantial, the genetic variants
identified in our study explain only a small part of the overall variance. Therefore, our SNPs
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probably have limited value in prediction of cardiovascular disease. Rare variants, common
variants with smaller effects, or variants which interact with other genetic and environmental
factors may explain the remaining variation in plasma fibrinogen levels.
Fibrinogen was measured independently in the six cohorts. Though methods for measuring
fibrinogen concentration were not standardized, they were all based on the Clauss method or
another clotting assay, except for KORA which used nephelometry. Nonetheless, the effect
estimates for the top SNPs were comparable between KORA and other studies.
Contributing studies used different genotyping platforms with different groups of SNPs. To
enable the meta-analysis, each study imputed ~2.5 million SNPs in HapMap CEU samples.
Imputation has previously been shown to be accurate and to increase the power. The power,
of course, would have been higher if all SNPs were genotyped in all studies.
In conclusion, we have identified four loci associated with fibrinogen levels through meta-
analysis of GWA data from six cohort studies comprising 22,096 subjects. All four loci
replicated in a seventh study. In addition, we replicated one of the two other loci which showed
a close to significant association in our meta-analysis and is biologically plausible. Three of
our findings (IRF1, PCCB, and NLRP3) represent newly identified associations. Among the
genes in the novel loci implicated in our study are those that encode proteins playing a role in
inflammation representing interesting targets for further research into biological pathways
involved in cardiovascular disease and other chronic inflammatory conditions.
Clinical summary
Fibrinogen is a major player in the coagulation system, is a determinant of platelet
aggregation, and affects blood viscosity. Circulating fibrinogen levels have been
consistently associated with risk of coronary heart disease. Although blood fibrinogen levels
are influenced by many environmental factors, genes either independently or in combination
with environmental factors play an important role in determining circulating fibrinogen
levels. The advent of genome-wide association studies provides an opportunity to identify
previously unsuspected genetic loci that influence complex traits. In this study, we
combined genome-wide association data from six large prospective cohort studies, and
identified four genetic loci that are associated with circulating fibrinogen levels. These
genetic loci provide valuable insights into the pathways that determine circulating
fibrinogen levels. Although additional investigations are needed to understand the exact
mechanisms, our findings do highlight the key contribution of inflammatory genes in
influencing inter-individual variation in fibrinogen levels. A better understanding of the
molecular mechanisms that control circulating fibrinogen levels may spur the development
of novel therapeutic strategies that might reduce fibrinogen levels. Such pharmacological
agents may be potentially useful for reducing the risk of coronary heart disease.
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Figure 1.
QQ-plot for the meta-analysis results. Quantile-quantile plot of the observed and the expected
distribution of p-values for all 2,661,766 SNPs and their association with fibrinogen levels
based on meta-analyzed data.
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Figure 2.
−Log plot for the meta-analysis. −Log p-values for each of the 2,661,766 tests performed as
part of the genome-wide association analysis of fibrinogen levels. The grey dashed horizontal
lines correspond to the p-value threshold of 5×10−8 and the grey solid line corresponds to
5×10−6.
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Figure 3.
Regional plots of loci associated with fibrinogen. (a-d). The association p-values (−log10
transformed, indicated by the left y-axis) for SNPs in a 60kb region of each of the four loci
(FGB, IRF1, PCCB, NLRP3) are plotted against their chromosome positions (NCBI build 36)
on x-axis. Each diamond represents a SNP with the color indicating the linkage disequilibrium
(estimated using HapMap CEU sample) between the SNP and the top associated SNP that is
plotted by a red diamond with size larger than all other diamonds, and with the SNP name
displayed on the top, and p-value on the right. Shown in light blue are the estimated
recombination rates in HapMap with values indicated by the right y-axis. The bottom panel
displays the genes in the region based on the UCSC Genome Browser March 2006 assembly,
with the arrow to right (left) indicate indicating +(−) strand. The grey horizontal line
corresponds to the p-value threshold of genome-wide significance, 5×10−8.
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